NCT00095173 - BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis | Biotech Hunter

Enrollment

214

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

June 30, 2006

Study Completion Date

November 30, 2011

Conditions

Juvenile Rheumatoid Arthritis

Interventions

DRUG

Abatacept

IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).

DRUG

Placebo

IV infusions, IV, N/A, every 4 weeks, 6 months.

DRUG

Abatacept

Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing \< 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing \> 100 kg, monthly

Trial Locations (36)

Unknown

Omaha

Livingston

New Hyde Park

Valhalla

Cincinnati

Cleveland

Duncansville

Dallas

Seattle

Milwaukee

Local Institution, Bregenz

Local Institution, Botucatu

Local Institution, Rio de Janeiro

Local Institution, São Paulo

Local Institution, Paris

Local Institution, Strasbourg

Local Institution, Berlin

Local Institution, Bremen

Local Institution, Halle

Local Institution, Hamburg

Local Institution, Florence

Local Institution, Genova

Local Institution, Milan

Local Institution, Napoli

Local Institution, Roma

Local Institution, Trieste

Local Institution, Guadalajara

Local Institution, Mexico City

Local Institution, Monterrey

Local Institution, Puebla City

Local Institution, San Luis Potosí City

Local Institution, Lima

Local Institution, Lisbon

Local Institution, A Coruña

Local Institution, Valencia

Local Institution, Lausanne